<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10944598</article-id><article-id pub-id-type="pmc">2363502</article-id><article-id pub-id-type="pii">6691305</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1305</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Paridaens</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Uges</surname><given-names>D R A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Barbet</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Seeghers</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Graaf</surname><given-names>W T A van der</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Groen</surname><given-names>H J M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dumez</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Buuren</surname><given-names>I Van</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Muskiet</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Capdeville</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Oosterom</surname><given-names>A T van</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vries</surname><given-names>E G E de</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Universitair Ziekenhuis Gasthuisberg, Herestraat 49, Leuven, 3000, Belgium</aff><aff id="aff2"><label>2</label>Academisch Ziekenhuis Groningen, Groningen, EZ, 9713, The Netherlands</aff><aff id="aff3"><label>3</label>Novartis Pharma AG, Lichtstrasse 35, Basel, CH-4002, Switzerland</aff><aff id="aff4"><label>4</label>Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ, 07936, USA</aff><aff id="aff5"><label>5</label>Novartis Pharma, PB 241, Arnhem, LZ, 6800, the Netherlands</aff><pub-date pub-type="epub"><day>16</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>5</issue><fpage>594</fpage><lpage>601</lpage><history><date date-type="received"><day>16</day><month>09</month><year>1999</year></date><date date-type="rev-recd"><day>08</day><month>03</month><year>2000</year></date><date date-type="accepted"><day>13</day><month>04</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Because tumour cell proliferation is highly dependent upon up-regulation of de-novo polyamine synthesis, inhibition of the polyamine synthesis pathway represents a potential target for anticancer therapy. SAM486A (CGP 48664) is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), more potent and specific than the first-generation SAMDC inhibitor methylglyoxal (bis) guanylhydrazone (MGBG). Preclinical testing confirmed promising antiproliferative activity. In this phase I study, SAM486A was given 4-weekly as a 120 h infusion. 39 adult cancer patients were enrolled with advanced/refractory disease not amenable to established treatments, PS &#x02264; 2, adequate marrow, liver, renal and cardiac function. Doses were escalated in 100&#x00025; increments without toxicity in 24 pts from 3 mg m<sup>&#x02013;2</sup>cycle<sup>&#x02013;1</sup>up to 400 mg m<sup>&#x02013;2</sup>cycle<sup>&#x02013;1</sup>. At 550 and 700 mg m<sup>&#x02013;2</sup>cycle<sup>&#x02013;1</sup>reversible dose-limiting neutropenia occurred. Other toxicities included mild fatigue, nausea and vomiting. No objective remission was seen. Pharmakokinetic analysis showed a terminal half-life of approximately 2 days. AUC and Cmax were related to dose; neutropenia correlated with AUC. The recommended dose for further phase II studies on this schedule is 400 mg m<sup>&#x02013;2</sup>cycle<sup>&#x02013;1</sup>. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>polyamine</kwd><kwd>SAMDC</kwd><kwd>phase I</kwd><kwd>5FU</kwd><kwd>neutropenia</kwd></kwd-group></article-meta></front></article>


